Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07368855 · ClinicalTrials.gov registry record · NA

GLP-1 Medicines and Mental Health Changes

A NA study, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
90
Enrollment target

NCT07368855 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07368855, a NA study, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target

Study Summary

Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality. Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.

Interventions

  • DRUG GLP-1

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-05-01
Est. Completion 2025-07-01
Phase NA

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT07368855

The ClinicalTrials.gov registry entry for NCT07368855 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which GLP-1 is the first listed.

NCT07368855 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07368855 about?

NCT07368855 is a clinical study titled "GLP-1 Medicines and Mental Health Changes". Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health...

What is the current status of trial NCT07368855?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2024-05-01. Estimated completion is 2025-07-01.

What interventions are being tested in trial NCT07368855?

The interventions under investigation include: GLP-1 (DRUG).

Who is sponsoring clinical trial NCT07368855?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.